Drugs / MenC-CRM
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01434680 | Sep 2011 → Nov 2012 | meningococcal meningitis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00310856 | Jun 2005 → Nov 2006 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00392808 | Jan 2007 → May 2008 | meningococcal infection | Center for Public Health Research | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00381615 Background | Sep 2006 → Jul 2007 | — | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenC-CRM | “previously primed with 3 doses of a MenC vaccine conjugated with CRM197 (MenC-CRM) or with 2 doses of a MenC vaccine conjugated with tetanus toxoid (MenC-TT), were randomized...” PMID 19927040 ↗ Feb 2010 |
| Modality | Vaccine | “Meningococcal C conjugate vaccine” NCT00310856 ↗ |
| Route | Intramuscular | “administered by IM injection into the arm region” NCT00310856 ↗ |